Zealand Pharma A/S (OTCMKTS:ZLDPF) Short Interest Update

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) saw a significant decrease in short interest in March. As of March 15th, there was short interest totalling 1,241,700 shares, a decrease of 31.5% from the February 28th total of 1,811,500 shares. Based on an average daily volume of 3,600 shares, the short-interest ratio is presently 344.9 days. Approximately 1.7% of the company's shares are sold short.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on ZLDPF shares. William Blair upgraded Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a report on Friday, March 7th. Cantor Fitzgerald raised shares of Zealand Pharma A/S to a "strong-buy" rating in a research note on Tuesday, January 21st.

Zealand Pharma A/S Stock Up 0.2 %

Shares of Zealand Pharma A/S stock traded up $0.15 during trading hours on Wednesday, reaching $67.31. 689 shares of the company were exchanged, compared to its average volume of 890. The firm has a market cap of $4.78 billion, a PE ratio of -28.52 and a beta of 0.92. The company has a debt-to-equity ratio of 0.03, a quick ratio of 35.49 and a current ratio of 35.49. Zealand Pharma A/S has a 1 year low of $66.40 and a 1 year high of $141.74. The stock's fifty day moving average is $92.34 and its 200 day moving average is $104.52.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.19. The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $28.11 million. Zealand Pharma A/S had a negative return on equity of 15.24% and a negative net margin of 1,725.03%. As a group, equities research analysts forecast that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.